| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| E L Konrath, B M Neves, C Dos S Passos, P S Lunardi, M G Ortega, J L Cabrera, C A Gonçalves, A T Henrique. Huperzia quadrifariata and Huperzia reflexa alkaloids inhibit acetylcholinesterase activity in vivo in mice brain. Phytomedicine : international journal of phytotherapy and phytopharmacology. vol 19. issue 14. 2013-04-26. PMID:23022390. |
thus, it appears that h. quadrifariata and h. reflexa alkaloid extracts, shown to inhibit acetylcholinesterase in vitro, also have very potent in vivo effects, suggesting that the huperzia species may still constitute a promising source of compounds with pharmaceutical interest for alzheimer's disease. |
2013-04-26 |
2023-08-12 |
mouse |
| Alzbeta Kracmarova, Hana Bandouchova, Jiri Pikula, Miroslav Pohank. Tacrine is implicated in oxidative stress in the laboratory guinea pig model. Neuro endocrinology letters. vol 33 Suppl 3. 2013-04-11. PMID:23353857. |
tacrine was the first acetylcholinesterase inhibitor approved for the treatment of alzheimer disease. |
2013-04-11 |
2023-08-12 |
Not clear |
| Andrius Baskys, Jin-xiang Chen. Pharmacological prevention and treatment of vascular dementia: approaches and perspectives. Experimental gerontology. vol 47. issue 11. 2013-04-04. PMID:22796225. |
pharmacological agents for treatment of alzheimer's dementia (ad) such as memantine or acetylcholinesterase inhibitors have small positive effects on cognition in vad, which are likely due to their action on co-existing ad-related neuropathology. |
2013-04-04 |
2023-08-12 |
Not clear |
| K Y Wong, P R Duchowicz, A G Mercader, E A Castr. QSAR applications during last decade on inhibitors of acetylcholinesterase in Alzheimer's disease. Mini reviews in medicinal chemistry. vol 12. issue 10. 2013-04-01. PMID:22303974. |
qsar applications during last decade on inhibitors of acetylcholinesterase in alzheimer's disease. |
2013-04-01 |
2023-08-12 |
Not clear |
| K Y Wong, P R Duchowicz, A G Mercader, E A Castr. QSAR applications during last decade on inhibitors of acetylcholinesterase in Alzheimer's disease. Mini reviews in medicinal chemistry. vol 12. issue 10. 2013-04-01. PMID:22303974. |
this article reviews multi-criteria qsar applications on acetylcholinesterase inhibitors as palliative drugs for alzheimer's disease, published in the period 2001-2011. |
2013-04-01 |
2023-08-12 |
Not clear |
| João P Lopes, Glauco Tarozzo, Angelo Reggiani, Daniele Piomelli, Andrea Cavall. Galantamine potentiates the neuroprotective effect of memantine against NMDA-induced excitotoxicity. Brain and behavior. vol 3. issue 2. 2013-03-28. PMID:23532860. |
the combination of memantine, an n-methyl-d-aspartate (nmda) receptor antagonist, with an acetylcholinesterase inhibitor (achei) is the current standard of care in alzheimer's disease (ad). |
2013-03-28 |
2023-08-12 |
rat |
| Da-Hua Shi, Zhi-Qiang Yan, Li-Na Zhang, Yu-Rong Wang, Chun-Ping Jiang, Jun-Hua W. A novel 7-O-modified genistein derivative with acetylcholinesterase inhibitory effect, estrogenic activity and neuroprotective effect. Archives of pharmacal research. vol 35. issue 9. 2013-03-19. PMID:23054722. |
to find the multi-target-directed compounds for the treatment of alzheimer's disease (ad), we synthesized 7-(4-(diethylamino)butoxy)-5-hydroxy-3-(4-hydroxyphenyl)-4h-chromen-4-one, a novel 7-o-modified genistein derivative (gs-14), and investigated its acetylcholinesterase (ache) inhibitory effect, estrogenic activity and neuroprotective effect. |
2013-03-19 |
2023-08-12 |
Not clear |
| Hamid Nadri, Morteza Pirali-Hamedani, Alireza Moradi, Amirhossein Sakhteman, Alireza Vahidi, Vahid Sheibani, Ali Asadipour, Nouraddin Hosseinzadeh, Mohammad Abdollahi, Abbas Shafiee, Alireza Foroumad. 5,6-Dimethoxybenzofuran-3-one derivatives: a novel series of dual Acetylcholinesterase/Butyrylcholinesterase inhibitors bearing benzyl pyridinium moiety. Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences. vol 21. issue 1. 2013-03-19. PMID:23445881. |
as a part of a research program to find a novel drug for treating alzheimer disease, we have previously reported 6-alkoxybenzofuranone derivatives as potent acetylcholinesterase inhibitors. |
2013-03-19 |
2023-08-12 |
Not clear |
| Diego Muñoz-Torrero, Pelayo Camp. Huprines for Alzheimer's disease drug development. Expert opinion on drug discovery. vol 3. issue 1. 2013-03-14. PMID:23480140. |
so far, acetylcholinesterase (ache) inhibitors have dominated the therapeutic arsenal for alzheimer's disease. |
2013-03-14 |
2023-08-12 |
Not clear |
| Bradford T Winslow, Mary K Onysko, Christian M Stob, Kathleen A Hazlewoo. Treatment of Alzheimer disease. American family physician. vol 83. issue 12. 2013-02-22. PMID:21671540. |
acetylcholinesterase inhibitors are first-line medications for the treatment of alzheimer disease, and are associated with mild improvements in cognitive function, behavior, and activities of daily living; however, the clinical relevance of these effects is unclear. |
2013-02-22 |
2023-08-12 |
Not clear |
| Bradford T Winslow, Mary K Onysko, Christian M Stob, Kathleen A Hazlewoo. Treatment of Alzheimer disease. American family physician. vol 83. issue 12. 2013-02-22. PMID:21671540. |
although n-methyl-d-aspartate receptor antagonists and acetylcholinesterase inhibitors can slow the progression of alzheimer disease, no pharmacologic agents can reverse the progression. |
2013-02-22 |
2023-08-12 |
Not clear |
| Anna Ziemianin, Cyril Ronco, Romain Dolé, Ludovic Jean, Pierre-Yves Renard, Catherine M Lang. Screening of new huprines--inhibitors of acetylcholinesterases by electrospray ionization ion trap mass spectrometry. Journal of pharmaceutical and biomedical analysis. vol 70. 2013-02-07. PMID:22677656. |
acetylcholinesterase inhibitors (achei) are one of the drugs families validated for clinical use in the treatment of alzheimer's disease (ad). |
2013-02-07 |
2023-08-12 |
human |
| Hai-Yan Zhan. New insights into huperzine A for the treatment of Alzheimer's disease. Acta pharmacologica Sinica. vol 33. issue 9. 2013-01-29. PMID:22941287. |
huperzine a, an active lycopodium alkaloid extracted from traditional chinese herb, is a potent, selective and reversible acetylcholinesterase (ache) inhibitor and has been widely used in china for the treatment of alzheimer's disease (ad). |
2013-01-29 |
2023-08-12 |
Not clear |
| Faviola Alcántara-González, Claudia Rebeca Mendoza-Perez, Néstor Zaragoza, Ismael Juarez, Luis Enrique Arroyo-García, Citlalli Gamboa, Fidel De La Cruz, Sergio Zamudio, Fernando Garcia-Dolores, Gonzalo Flore. Combined administration of cerebrolysin and donepezil induces plastic changes in prefrontal cortex in aged mice. Synapse (New York, N.Y.). vol 66. issue 11. 2013-01-09. PMID:22826038. |
cerebrolysin (cbl) shows neurotrophic and neuroprotective properties while donepezil (dnp) is a potent acetylcholinesterase (ache) inhibitor, both drugs are prescribed for alzheimer's disease (ad) treatment. |
2013-01-09 |
2023-08-12 |
mouse |
| Dingbin Liu, Wenwen Chen, Yue Tian, Sha He, Wenfu Zheng, Jiashu Sun, Zhuo Wang, Xingyu Jian. A highly sensitive gold-nanoparticle-based assay for acetylcholinesterase in cerebrospinal fluid of transgenic mice with Alzheimer's disease. Advanced healthcare materials. vol 1. issue 1. 2013-01-03. PMID:23184691. |
a highly sensitive gold-nanoparticle-based assay for acetylcholinesterase in cerebrospinal fluid of transgenic mice with alzheimer's disease. |
2013-01-03 |
2023-08-12 |
mouse |
| George Bartzoki. Neuroglialpharmacology: myelination as a shared mechanism of action of psychotropic treatments. Neuropharmacology. vol 62. issue 7. 2012-12-20. PMID:22306524. |
similarly, psychotropic treatments ranging from lithium and antipsychotics to serotonin reuptake inhibitors (ssris) and acetylcholinesterase inhibitors have been shown to be efficacious in a wide spectrum of psychiatric disorders ranging from autism, schizophrenia (sz), depression, and bipolar disorder (bd) to alzheimer's disease (ad). |
2012-12-20 |
2023-08-12 |
human |
| Zhenxin Zhang, Lu Yu, Maren Gaudig, Barbara Schäuble, Ute Richar. Galantamine versus donepezil in Chinese patients with Alzheimer's disease: results from a randomized, double-blind study. Neuropsychiatric disease and treatment. vol 8. 2012-12-13. PMID:23233806. |
acetylcholinesterase inhibitors are considered standard of care for alzheimer's disease in many countries. |
2012-12-13 |
2023-08-12 |
Not clear |
| Hailin Zheng, Mati Fridkin, Moussa B H Youdi. Novel chelators targeting cell cycle arrest, acetylcholinesterase, and monoamine oxidase for Alzheimer's therapy. Current drug targets. vol 13. issue 8. 2012-12-10. PMID:22676912. |
novel chelators targeting cell cycle arrest, acetylcholinesterase, and monoamine oxidase for alzheimer's therapy. |
2012-12-10 |
2023-08-12 |
Not clear |
| Hailin Zheng, Mati Fridkin, Moussa B H Youdi. Novel chelators targeting cell cycle arrest, acetylcholinesterase, and monoamine oxidase for Alzheimer's therapy. Current drug targets. vol 13. issue 8. 2012-12-10. PMID:22676912. |
the recent finding that acetylcholinesterase (ache) colocalizes with β-amyloid (aβ), promotes and accelerates aβ aggregation has renewed an intense interest in developing new multitarget ache inhibitors as potential disease-modifying drugs for alzheimer's therapy. |
2012-12-10 |
2023-08-12 |
Not clear |
| Wei Zheng, Juan Li, Zhuibai Qiu, Zheng Xia, Wei Li, Lining Yu, Hailin Chen, Jianxing Chen, Yan Chen, Zhuqin Hu, Wei Zhou, Biyun Shao, Yongyao Cui, Qiong Xie, Hongzhuan Che. Novel bis-(-)-nor-meptazinol derivatives act as dual binding site AChE inhibitors with metal-complexing property. Toxicology and applied pharmacology. vol 264. issue 1. 2012-11-19. PMID:22842334. |
the strategy of dual binding site acetylcholinesterase (ache) inhibition along with metal chelation may represent a promising direction for multi-targeted interventions in the pathophysiological processes of alzheimer's disease (ad). |
2012-11-19 |
2023-08-12 |
human |